One group xenografted humanized mice with human colorectal cancer or gastric cancer cells and treated them with nivolumab, a PD-1 inhibitor, and urelumab, a 4-1BB (CD137) agonist, alone and in combination, to evaluate their anti-tumor properties65. This evidence concerns the gene TNFRSF9 and colorectal cancer.